Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 60

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 60
---
CONDENSED
BALANCE SHEETS

    March
    31,  
    December
    31, 

    2025 (unaudited)  
    2024

    ASSETS 

    Current
    assets: 

    Cash and cash equivalents  
    $402,999  
    $1,266,131 
  
    Prepaid
    expenses 
     88,189  
     57,874 
  
    Total
    current assets 
     491,188  
     1,324,005 

    Total
    assets 
    $491,188  
    $1,324,005 

    LIABILITIES
    AND STOCKHOLDERS’ EQUITY (DEFICIT) 

    Current
    liabilities: 

    Trade
    accounts payable and accrued liabilities 
    $558,862  
    $587,536 
  
    Due
    to related parties 
     93,432  
     93,432 
  
    Total
    current liabilities 
     652,294  
     680,968 

    Total
    liabilities 
    $652,294  
    $680,968 

    Stockholders’
    Equity (Deficit) 

    Preferred
    Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common
    Stock, no par value; 300,000,000 shares authorized, 29,762,671 and 29,762,671 shares issued and outstanding at March 31, 2025 and
    December 31, 2024, respectively. 
     -  
     - 
  
    Additional
    paid-in capital 
     32,615,580  
     31,239,895 
  
    Accumulated
    deficit 
     (32,776,686) 
     (30,596,858)
  
    Total
    stockholders’ equity (deficit) 
     (161,106) 
     643,037 
  
    Total
    liabilities and stockholders’ equity (deficit) 
    $491,188  
    $1,324,005 

See notes to condensed unaudited financial statements

3

TELOMIR
PHARMACEUTICAL